Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
- PMID: 36924123
- PMCID: PMC10121302
- DOI: 10.3350/cmh.2023.0106
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
Keywords: China; Hepatectomy; Hepatocellular carcinoma; Immunotherapy; Molecular targeted therapy.
Conflict of interest statement
The authors have no conflicts to disclose.
Comment on
-
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.Clin Mol Hepatol. 2023 Apr;29(2):206-216. doi: 10.3350/cmh.2022.0402. Epub 2022 Dec 22. Clin Mol Hepatol. 2023. PMID: 36545708 Free PMC article. Review.
References
-
- Yang T, Lu JH, Wu MC. Hepatocellular carcinoma in China. BMJ (Clinical research ed.) 2010;340:c1026.
-
- Yang T, Zhang H, Lau WY, Shen F, Wu MC. Liver disease in China: A long way to go. Hepatology. 2015;62:1640. - PubMed
-
- Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73:1368–1378. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
